Pay in 4 interest-free payments of $6.76 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Appetite changes often get clearer in this window
This intelligence helps your prescriber fine-tune your treatment protocol for maximum efficacy
5 Market outlook Eli Lillys oral non-peptide GLP-1RA orforglipron is advancing through the ACHIEVE Phase III program, with Lilly signaling regulatory submissions for obesity in 2025 and type 2 diabetes in 2026, following positive results from both Phase 2 obesity (GZGI) and Phase 3 T2DM (ACHIEVE-1) trials
Because glucagon-receptor agonism could theoretically raise glucose, the phase 2 program specifically examined participants with type 2 diabetes and found that retatrutide lowered HbA1c rather than raising it evidence that the molecules GLP-1 and GIP activity more than offsets any glucagon-driven glucose elevation
The Gallup poll also found that the percentage of Americans with obesity decreased from 39.9% in 2022 to 37.0% in 2025, a three-percentage-point decrease that represents 7.6 million people
